

ondine



For Immediate Release

**Ondine Reports Positive Results from its Third Consecutive Trial of Periowave™
Gum Disease Therapy**

Vancouver, Canada – February 6, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced results of its Periowave™ clinical study at the University of British Columbia, in Vancouver, BC, Canada. This 40 patient trial was designed to evaluate Periowave™ adjunctive therapy in the well-maintained, non-smoking periodontal patient. This is the third consecutive trial of Periowave™ where statistically and clinically significant outcomes have been proven in the treatment of chronic adult periodontitis.

Ondine plans to submit a late-breaking abstract from this trial to the combined meetings of the International Association for Dental Research (IADR) and the American Association for Dental Research (AADR) meeting in New Orleans, March 21-24, 2007. The IADR/AADR meeting is expected to attract 5000 dental researchers from around the world who are dedicated to the prevention and treatment of oral and dental diseases.

The UBC trial focused on the well-maintained, non-smoking periodontal patient who had been receiving the gold-standard therapy of scaling and root planing (SRP) every three months, but whose periodontal disease had nevertheless not responded well to this traditional therapy. These patients are considered the most difficult to treat because of the refractory nature of their disease.

In 33% of treated subjects, Periowave™ therapy resulted in average pocket depth recoveries exceeding 1.5 mm. None of the subjects in the control arm experienced recoveries of this magnitude.

“Average pocket depth recoveries greater than 1.5 mm in refractory patients are rarely seen using SRP alone,” said Dave Hammond, Director of Clinical for Ondine Biopharma. “This trial demonstrated that even in the toughest patients, Periowave™ is an effective adjunctive therapy that can significantly improve periodontal health.”

About Periowave™ and Photodynamic Disinfection

Periowave™ is a Photodynamic Disinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodynamic Disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation:

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodynamic Disinfection (PDD) provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine has developed Periowave™ for the treatment of chronic periodontitis and endodontics, and is extending its platform technology into other applications both within and outside the oral cavity.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA, a sales and marketing subsidiary in York, Pennsylvania, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

For further information please contact:

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
ccross@ondinebiopharma.com	cbessant@equicomgroup.com